胰岛素抵抗
肠道菌群
生物
中医药
抗性(生态学)
代谢组学
胰岛素
计算生物学
医学
生物信息学
生物技术
生物化学
生态学
病理
替代医学
作者
Jing Liu,Fuxing Li,Le Yang,Suyi Luo,Yihui Deng
标识
DOI:10.3389/fmicb.2025.1554189
摘要
The gut microbiota is closely associated with the onset and development of type 2 diabetes mellitus (T2DM), characterized by insulin resistance (IR) and chronic low-grade inflammation. However, despite the widespread use of first-line antidiabetic drugs, IR in diabetes and its complications continue to rise. The gut microbiota and its metabolic products may promote the development of T2DM by exacerbating IR. Therefore, regulating the gut microbiota has become a promising therapeutic strategy, with particular attention given to probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. This review first examines the relationship between gut microbiota and IR in T2DM, summarizing the research progress of microbiota-based therapies in modulating IR. We then delve into how gut microbiota-related metabolic products contribute to IR. Finally, we summarize the research findings on the role of traditional Chinese medicine in regulating the gut microbiota and its metabolic products to improve IR. In conclusion, the gut microbiota and its metabolic products play a crucial role in the pathophysiological process of T2DM by modulating IR, offering new insights into potential therapeutic strategies for T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI